TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

FDA Approves Amgen's Drug For Rare Muscle Disorder

Benzinga Logo Benzinga By Vandana Singh
FDA Approves Amgen's Drug For Rare Muscle Disorder

The FDA approved Amgen's drug Uplinza for generalized myasthenia gravis (gMG), offering a new targeted treatment option for adult patients with specific antibody conditions, requiring only two doses annually after initial loading doses.

Insights
MSFT   neutral

Significant holding in both ETFs with standard market representation


AMGN   positive

Received FDA approval for a new drug indication, expanding treatment options for a rare muscle disorder, which could potentially increase market share and revenue